Cyclerion Therapeutics, Inc.
CYCN
NASDAQ·Healthcare·Biotechnology·Mkt cap $23.2M
$4.25
▼ -14.31%
P/E
-2.47
Mkt Cap
$23.2M
52-Wk Range
$1.03–$8.48
52-Week Range
$1.03 - $8.48
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 107.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary sGC stimulator platform technology targeting multiple disease indications
- CNS-penetrant drug candidates addressing high unmet medical needs in neurodegeneration
- Strategic partnerships and licensing agreements expanding development capabilities
- Diverse pipeline reducing single-program risk while maximizing market opportunities
Bear Case
1 risk
- Above-average volatility (beta 1.7).
Growth
Stable outlook
Advancement of CY6463 through Phase IIa trials for Alzheimer's disease and CNS indications
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+62.1% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CYCN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 11, 2026
AUG 4, 2026
Reported EPS of -$0.41 vs -$7.10 consensus (+94.2% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+94.2%
Revenue trend · last 8Q
—
—
—
—
+351%
-43%
-100%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$194.0K
$1.8M
$81.0K
$93.0K
$875.0K
$1.0M
$0
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How CYCN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related